Home/Filings/4/0000920465-20-000025
4//SEC Filing

Wellinghoff Darryl 4

Accession 0000920465-20-000025

CIK 0000920465other

Filed

Feb 3, 7:00 PM ET

Accepted

Feb 4, 4:01 PM ET

Size

7.0 KB

Accession

0000920465-20-000025

Insider Transaction Report

Form 4
Period: 2020-01-31
Wellinghoff Darryl
Chief Commercial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2020-01-31+282282 total
    Exercise: $6.85Exp: 2030-01-31Common Stock (282 underlying)
  • Award

    Common Stock

    2020-01-31$5.82/sh+282$1,6418,015 total
Footnotes (2)
  • [F1]These shares were acquired on 01/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
  • [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.

Issuer

LA JOLLA PHARMACEUTICAL CO

CIK 0000920465

Entity typeother

Related Parties

1
  • filerCIK 0001770350

Filing Metadata

Form type
4
Filed
Feb 3, 7:00 PM ET
Accepted
Feb 4, 4:01 PM ET
Size
7.0 KB